Stock Chart
NVAX
This target is derived from long-term trendline analysis and projected growth.
Note: Targets are based on the assumption that the current primary trend continues. They should be used as reference points, not guarantees.
Target may adjust dynamically as the stock trend reverses or accelerates.
Type: SELL growth_1yr
Strike: $10
Premium: $2.10
Expiry: Jan 15, 2027
Target: $9
Score: -100
LEAPs are long-term options (1+ year) with less time decay.
This is a PROJECTED price range based on extrapolating the current trendline slope forward 30 days.
How it works:
• Draws support and resistance trendlines
• Calculates slope (rate of change)
• Projects lines to 30 days future
Signals:
● STRONG_UPTREND: Steep rise
● UPTREND: Moderate rise
● SIDEWAYS: Flat/Mixed
● DOWNTREND: Falling
⚠️ Not a prediction. Shows trend projection only.
R-squared: 0.08
Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech
Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity
Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
About NVAX - Novavax Inc
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business …
Key Statistics
More NVAX Analysis
This NVAX stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track NVAX's price movements with trendlines, gamma walls, and key support/resistance levels.